NCT03246607

Brief Summary

This study evaluates the validity of an intravascular continuous glucose monitoring microdialysis probe, and compares the values to routinely inserted cerebral glucose microdialysis to evaluate the hypothesised relationship between intracranial and intravascular glucose levels.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 11, 2017

Completed
2.5 years until next milestone

Study Start

First participant enrolled

January 26, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 2, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2020

Completed
Last Updated

July 2, 2019

Status Verified

July 1, 2019

Enrollment Period

6 months

First QC Date

August 9, 2017

Last Update Submit

July 1, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Continuously measured intravascular glucose concentration

    Study inserted microdialysis catheter for collection of data on the concentration of glucose in this space.

    72 hours

Secondary Outcomes (2)

  • Intermittently measured intravascular glucose concentration

    72 hours

  • Cerebral extracellular fluid glucose concentration

    72 hours

Study Arms (1)

Monitoring with MicroEye & ContinuMon

72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.

Device: MicroEye & ContinuMon

Interventions

Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.

Monitoring with MicroEye & ContinuMon

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are admitted to the Neurocritical Care Unit with a severe acquired brain injury

You may qualify if:

  • Aged 16 and over
  • New episode of acquired brain injury, of any form to include haemorrhage, trauma, infarction
  • Their condition necessitates admission to and care on neurocritical care
  • Their condition necessitates intracerebral microdialysis probe insertion
  • Their condition necessitates arterial line insertion/central venous access and regular/venous blood gas sampling.

You may not qualify if:

  • Pregnancy.
  • Peripheral venous cannulation clinically contraindicated.
  • Patients already enrolled in three or more other research studies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cambridge University Hospitals NHS Foundation Trust

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

Location

MeSH Terms

Conditions

Brain Injuries, TraumaticBrain InjuriesCerebral HemorrhageSubarachnoid HemorrhageIschemic Stroke

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and InjuriesIntracranial HemorrhagesCerebrovascular DisordersVascular DiseasesCardiovascular DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsStroke

Study Officials

  • Ari Ercole, PhD

    Lecturer and Consultant Anaesthetist

    PRINCIPAL INVESTIGATOR
  • Peter Hutchinson, PhD

    NIHR Research Professor at the Department of Clinical Neurosciences

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrew R Stevens, MBChB

CONTACT

Ari Ercole, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Academic Foundation Doctor

Study Record Dates

First Submitted

August 9, 2017

First Posted

August 11, 2017

Study Start

January 26, 2020

Primary Completion

August 2, 2020

Study Completion

October 1, 2020

Last Updated

July 2, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations